Evaluating dexamethasone for severe influenza
Official title: Randomized, Double-blind, Multicenter, Phase III Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza
Run by Instituto de Investigación Sanitaria y Biomédica de Alicante · NCT06528444 · Data updated 2026-11-12
This study is testing whether the medication dexamethasone can help hospitalized patients with severe influenza recover better than those who receive a placebo.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Enrollment | 42 (estimated) |
| Sponsor | Instituto de Investigación Sanitaria y Biomédica de Alicante Research network |
| Drugs / interventions | prednisone |
| Locations | 2 sites (Alicante and 1 other locations) |
| Status | Recruiting |
| Started | October 1, 2024 |
| Main results expected | October 31, 2028 |
| Study ends | October 31, 2028 |
| Registry record updated | February 19, 2025 |
| Trial ID | NCT06528444 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are hospitalized adults aged 18 years and older with a confirmed diagnosis of severe influenza.
✕Probably not a fit
Patients with bronchial hyperresponsiveness requiring systemic corticosteroids or those on ECMO may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a randomized, double-blind, multicenter phase III evaluation of dexamethasone's efficacy and safety compared to a placebo in patients diagnosed with severe influenza. Participants must be hospitalized and have a confirmed diagnosis of influenza A or B virus infection. The study aims to determine whether dexamethasone can improve patient outcomes in this population. The trial will involve administering either dexamethasone or a placebo to eligible patients and monitoring their recovery.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for patients suffering from severe influenza.
How similar studies have gone: Other studies have explored corticosteroids in viral infections, but the specific use of dexamethasone for severe influenza is less established, making this approach somewhat novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged ≥ 18 years. 2. Diagnosis of influenza A or B virus infection by antigen or RT-PCR (local laboratory) at the time of entry or at 48 hours prior to randomization in respiratory specimens (nasopharyngeal swab or bronchoalveolar lavage). 3. Hospitalized patients with an estimated hospital stay of more than 24 hours. 4. In previous treatment or concomitant start of treatment with oseltamivir. 5. For women of childbearing age, use of contraceptive methods until day 30 after completion of treatment. 6. Signed informed consent. Exclusion Criteria: * 1\. Patients with bronchial hyperresponsiveness that requires systemic corticosteroids for more than 24 hours. 2\. Pre-inclusion treatment with corticosteroids for more than 24 hours at a dose equal to or higher than 1 mg/kg methyl-prednisolone (0.2 mg/kg dexamethasone or 1.25 mg/kg prednisone). 3\. Inability to administer oral oseltamivir. 4. Patients on ECMO (extracorporeal membrane oxygenation). 5. Pre-existing condition or use of medication that, in the opinion of the local investigator, may pose a risk for the administration of corticosteroids. 6\. Patients with severe comorbidity with life expectancy of less than six months in the opinion of the investigator. 7\. Patients co-infected with SARS-CoV-2 or RSV.
Where it's running
-
Hospital General Universitario Dr. Balmis de Alicante (centro coordinador)
Alicante, Spain Recruiting -
Hospital General Universitario de Elche
Elche, Spain Recruiting
Study contacts
- Study coordinator: Javier Mateo, Biologist
- Email: mateo_jav@isabial.es
- Phone: 965
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy
This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.
-
Abbott ID NOW at the point of care for flu-like illness in long-term care facilities
This trial tests whether the Abbott ID NOW rapid test at the point of care in long-term care facilities can help identify influenza sooner for residents 65 and older with fever and respiratory symptoms.
-
Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults
This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.
-
Safety and PK of Ingavirin Forte vs Ingavirin in healthy adults under fasting and fed conditions
This early-phase study tests whether Ingavirin Forte (90 mg + 20 mg) is safe and how it behaves in the body compared with Ingavirin (90 mg) in healthy adults aged 18–45, under different meal conditions.
-
Light-based immune boost to help prevent viral upper respiratory infections
A daily handheld light therapy device is tested to see if it can lower how often adults at a military medical facility get colds, flu, or other upper respiratory infections.
-
Virological Monitoring of Seasonal Respiratory Infections in France
This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.